The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | The growing role of combination approaches in MF & agents being explored
In this video, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses unmet needs in patients with myelofibrosis (MF) treated with JAK inhibitors, highlighting that many patients may lose response to these agents. Prof. Kiladjian explains that combination approaches may be of benefit, and further discusses agents being explored in combination with ruxolitinib, including navitoclax, pelabresib, and navtemadlin. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
